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Abstract
Background: Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM),
which is one of the major active metabolites of tamoxifen (TAM). Homozygous SULT1A1 variant allele genotype has
been associated with lower catalytic activity and thermostability of the enzyme. Previous clinical studies suggest
that the SULT1A1 rs9282861 polymorphism may influence the survival of breast cancer patients treated with TAM
in the adjuvant setting. We investigated the effect of rs9282861 genotypes on the survival of Finnish breast cancer
patients treated with adjuvant chemotherapy or TAM.
Methods: The rs9282861 genotypes of 412 Finnish breast cancer patients with early breast cancer were identified
by using PCR-RFLP method. Seventy six patients were treated with adjuvant cyclophosphamide based
chemotherapy only, 65 patients received adjuvant TAM, and four patients were treated with both adjuvant
chemotherapy and TAM. Overall long-term survival (OS), breast cancer specific survival (BCSS), and relapse-free
survival (RFS) by rs9282861 genotypes were evaluated by the Kaplan-Meier method and Cox regression analysis.
Results: The multivariate analysis of 145 patients receiving either adjuvant TAM or chemotherapy showed a
statistically significantly improved OS in patients with the rs9282861 homozygous variant AA genotype (hazard
ratio [HR] = 0.50, 95% confidence interval [CI] = 0.29-0.88, P = 0.015). In the separate analyses of patients receiving
only chemotherapy or adjuvant TAM, there were no statistically significant differences in survival.
Conclusions: In this prospective study, we observed a previously unreported association between the SULT1A1
rs9282861 genotype and OS of breast cancer patients treated with adjuvant chemotherapy or TAM. This novel
finding suggests that the rs9282861 polymorphism modifies the long-term clinical outcome of patients receiving
adjuvant TAM or chemotherapy.
Background
Tamoxifen (TAM) has been used for the treatment of oes-
trogen-receptor-positive breast cancer for three decades
and still has its place in the treatment of both early and
metastatic breast cancer. In the adjuvant setting it is the
preferred endocrine therapy in premenopausal women
and an acceptable option in postmenopausal women,
especially in the group with low risk of relapse [1]. In early
stage breast cancer, TAM reduces the 15-year risks of
breast cancer recurrence and death by about a third [2].
Even though the benefit of adjuvant TAM persists for
years, some patients will eventually relapse and die of
breast cancer [2]. In addition to causing hot flushes TAM
increases the risk of endometrial cancer and thromboem-
bolic complications [3,4].
The most important metabolites of TAM in terms of
therapeutic efficacy are 4-hydroxy-TAM (4-OH-TAM) and
4-OH-N-desmethyl-TAM (endoxifen) [5]. The detoxifica-
tion of 4-OH-TAM is catalyzed by the phase II enzymes
human sulfotransferase 1A1 (SULT1A1) and uridine
diphosphate glucuronosyltransferase isoform 2B15
(UGT2B15) [6]. SULT1A1 is a member of the sulfotrans-
ferase family, which has the capability to sulphate phenolic
and steroid compounds. A G683A base substitution
(rs9282861) in exon 7 of SULT1A1 results in an Arg213His
amino acid change with functional consequences; the
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activity and thermostability compared with the wild-type G
allele [7]. The impact of SULT1A1 rs9282861 genotype on
the risk of breast cancer and response to TAM therapy has
been reported in several studies; the variant AA genotype
has been associated both with poorer overall survival (OS)
[8] and with no effect on OS [9,10], whereas patients with
the homozygous wild-type GG genotype have been
reported to have a tendency towards improved distant
recurrence-free survival (RFS) [11].
In the 1970s Bonadonna et al. [12] presented the adju-
vant chemotherapy regimen of cyclophosphamide (CPA),
methotrexate, and 5-fluorouracil (CMF). This has been
shown to significantly decrease the relative risk of relapse
and death compared with no systemic treatment [13].
Newer agents such as anthracyclines and taxanes have
further improved the survival of breast cancer patients
[2,14]. CPA containing combinations are standard thera-
pies in the adjuvant treatment of breast cancer [1,15]. The
intravenous (i.v.) CMF (CPA 500 mg/m
2, methotrexate
40 mg/m
2, 5-fluorouracil 500 mg/m
2) is a modification of
the classical CMF, and it has been used in Finland as a
standard adjuvant treatment, especially in the late 1980s
and early 1990s.
To date, there are no published data on the effect of the
SULT1A1 rs9282861 single nucleotide polymorphism
(SNP) on the outcome of adjuvant chemotherapy or the
long-term survival of breast cancer patients. However,
there is evidence that SNPs of the genes coding for drug-
metabolising enzymes may influence the outcome of che-
motherapy. CPA is a pro-drug that is converted into the
active cytotoxic alkylating phosphoramide mustard through
the formation of 4-hydroxy-CPA (4-OHCPA) and its tau-
tomer aldophosphamide [16]. SNPs of the cytochrome
P450 (CYP) genes that are involved in the bioactivation of
CPA, i.e., CYP2B6, CYP2C9, CYP2C19 and CYP3A4/5,
may affect CPA pharmacokinetics [17-19]. Moreover, there
is some evidence that polymorphisms of detoxifying glu-
tathione-S-transferases (GSTs) may have an influence on
the outcome of CPA treatment; homozygous variant
GSTA1*B/*B genotype was related to reduced mortality
during the first 5 years after diagnosis of breast cancer [20]
and the low activity associated GSTP1 Val105Val genotype
has been reported to confer to better survival [21].
In this prospective study, our aim was to determine
whether SULT1A1 rs9282861 SNP influences the long-
term survival of breast cancer patients receiving adjuvant
chemotherapy or TAM.
Methods
Study population
The Kuopio Breast Cancer Project is a prospective case-
control study that was conducted in 1990-1995 and was
approved by the Kuopio University Hospital Board of
Research Ethics. Briefly, women who were referred to
Kuopio University Hospital due to breast symptoms
were invited to take part in the study at their first visit
to the hospital. The subjects provided written informed
consent for the study. Extensive data regarding medical
history, family history of breast cancer, socioeconomic
background, alcohol use, and cigarette smoking were
collected from the patients.
dAltogether 520 women out of 1,919 were eventually
diagnosed to have breast cancer. All patients were ethnic
Finns. Hospital registries were used to collect informa-
tion concerning clinicopathological features of the breast
cancer, type and duration of treatment, and follow-up.
For this particular study, patients who had carcinoma in
situ, metastatic disease at presentation, unknown nodal
status, prior history of breast cancer or refused surgery
were excluded (n = 78). The SULT1A1 rs9282861 geno-
type data were available for 412 eligible patients.
There were 84 patients who received adjuvant TAM
but no chemotherapy. Of these, five women were
excluded because of the very short duration of TAM
treatment, namely less than three months, and 14
patients were further excluded due to negative or
unknown estrogen receptor (ER) status. Thus, 65 TAM
treated patients were ultimately included in the planned
analyses. In this group, the median duration of adjuvant
TAM therapy was 36 months (range 3-75). Forty seven
patients received a daily dosage of 20 mg TAM and 18
patients received a daily dosage of 40 mg TAM.
The rs9282861 genotype data were available for 76
patients who were treated with chemotherapy as their
only systemic adjuvant treatment. Seventy patients were
treated with CMF, whereas six patients received CNF
(CPA 500 mg/m
2, mitoxantrone 10 mg/m
2 and 5-fluor-
ouracil 500 mg/m
2). The median number of cycles was
six (range 2-6). Four patients were treated with both
adjuvant TAM and chemotherapy.
Data on breast cancer risk associated with various
genetic polymorphisms in this study population have
previously been reported by Mitrunen, Sillanpää and
Hartikainen, and coworkers [22-24].
Genotyping
One hundred ng of the DNA were used as a template in
the genotyping analyses using a PCR-RFLP based
method as reported by Engelke et al. [25]. Samples with
known genotypes and nontemplate samples were used
as positive and negative internal controls, respectively.
Duplicates of 10% of the samples were blindly analyzed
for quality control with fully concordant results.
Statistical evaluation
The data on survival and causes of death were obtained
from hospital registries which utilize the national
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either as caused by breast cancer or not caused by
breast cancer. OS and breast cancer specific survival
(BCSS) were calculated from the date of diagnosis to the
last follow-up date or date of death. RFS was recorded
from time of diagnosis to time of first relapse (local
relapse, contra lateral breast cancer or metastatic dis-
ease) or the end of follow-up. The causes of death are
specified according to the SULT1A1 rs9282861 genotype
in the Additional file 1: Table S1, Table S2 and Table
S3.
Statistical analyses were conducted using SPSS version
17.0. The impact of SULT1A1 rs9282861 genotype on
RFS, BCSS, and OS were first calculated by using uni-
variate Kaplan-Meier survival analysis and the signifi-
cance of the differences detected between groups was
assessed by the log-rank test. The survival was estimated
for the homozygous carriers of the G allele compared
with the carriers of the variant A allele, as well as for
homozygous carriers of the variant allele compared with
the carriers of the wild-type allele.
The P-values, and the hazard ratios (HRs) and their
95% confidence intervals (CIs) were calculated using
Cox proportional hazards models adjusted for potential
confounders. The P-value ≤ 0.05 was considered to be
statistically significant.
Results
Allele and genotype distribution in relation to subject
characteristics
Data on the patient characteristics and genotypes of the
whole study population are presented in Table 1. The
median age of the patients at the time of diagnosis was
56 years (range 23-91 years). The median follow-up
time at the cut-off in February 2011 for the total study
population was 11.9 years (range 0.1-20.4 years).
The rs9282861 genotypes were in Hardy-Weinberg
equilibrium in the whole study population. The wild-
type G allele frequency was 53% in the whole study
population (n = 412), 46% in the TAM-treated group (n
= 65), and 61% in the chemotherapy treated group (n =
76). In the TAM-treated group the frequencies of the
rs9282861 GG, AG and AA genotypes were 20.0%,
52.3% and 27.7%, respectively. In the group of che-
motherapy treated patients the respective genotype fre-
quencies were 40.8%, 40.8% and 18.4%.
Rs9282861 SNP and survival of patients receiving
adjuvant chemotherapy
In the Kaplan-Meier OS analysis the SULT1A1
rs9282861 homozygous variant AA genotype emerged as
a statistically significant favourable genotype compared
with other genotypes (log-rank P = 0.045). A similar
although statistically insignificant pattern was seen in
BCSS (log-rank P = 0.075) (Additional file 3: Figure S2).
In the recessive model after adjusting for age, stage of
disease at diagnosis, adjuvant radiation therapy and oes-
trogen and progesterone receptor status, Cox regression
analysis showed no statistically significant differences in
OS (HR = 0.33, 95% CI = 0.10-1.09, P = 0.068) (Figure
1, Table 2), neither did the BCSS differ significantly (HR
= 0.36, 95% CI = 0.11-1.20, P = 0.095) (data not shown).
All three deaths among carriers of the homozygous var-
iant genotype were caused by breast cancer, whereas
among the carriers of the GG and AG genotypes 29
patients died of breast cancer and only three deaths
were due to other causes. In contrast, RFS did not differ
significantly between the different rs9282861 genotype
groups (log-rank P = 0.17).
Rs9282861 SNP and survival of patients receiving
adjuvant TAM
In the multivariate analysis adjusting for age, stage and
adjuvant radiation therapy, the OS did not differ signifi-
cantly between the patients homozygous for the variant
A allele and the patients carrying the wild-type G allele
(HR = 0.53, 95% CI = 0.27-1.08, P = 0.079) (Figure 2,
Table 2). In terms of BCSS or RFS, there were no statis-
tically significant differences according to the rs9282861
genotype. The Kaplan-Meier curves for BCSS are shown
in the Additional file 3: Figure S2.
Influence of the rs9282861 SNP on survival of the
combined patient population receiving adjuvant TAM or
chemotherapy
Altogether 141 patients received either chemotherapy or
TAM as their adjuvant treatment. In addition, four
patients were given both chemotherapy and TAM. The
univariate analysis of these 145 patients detected a sig-
nificant difference in OS (log-rank P = 0.042). The
BCSS did not differ significantly (log-rank P = 0.088)
(Additional file 4: Figure S3). After adjusting for age,
stage, adjuvant radiation therapy, and hormone receptor
status, the multivariate analysis showed that patients
with the homozygous variant rs9282861 AA genotype
had statistically significantly improved OS (HR = 0.50,
95% CI = 0.29-0.88, P = 0.015) (Figure 3, Table 2). A
parallel although statistically insignificant pattern was
seen in BCSS (HR = 0.53, 95% CI = 0.26-1.05, P =
0.069). No statistically significant difference was seen in
the RFS (P = 0.091).
In the dominant model there were no statistically signif-
icant differences in survival in any of the treatment
groups. In contrast to the adjuvant chemotherapy or
TAM treated patients the SULT1A1 rs9282861 SNP did
not have any influence on the survival of patients not
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the rs9282861 genotypes did not appear as a prognostic
factor in the survival analyses for the whole study popu-
lation (n = 412).
Discussion
The aim of this study was to determine whether the
SULT1A1 rs9282861 genotype is associated with clinical
outcome of patients diagnosed with early breast cancer
Table 1 Distribution of the SULT1A1 rs9282861 genotypes in relation to the subject characteristics
§
rs9282861 genotype
Characteristics All subjects (n = 412) GG (n = 121) AG (n = 194) AA (n = 97)
Age at diagnosis, years
≤ 39 37 (9.0) 14 (37.8) 15 (40.5) 8 (21.6)
40-49 98 (23.8) 34 (34.7) 40 (40.8) 24 (24.5)
50-59 104 (25.2) 29 (27.9) 51 (49.0) 24 (23.1)
60-69 65 (15.8) 16 (24.6) 36 (55.4) 13 (20.0)
≥ 70 108 (26.2) 28 (25.9) 52 (48.1) 28 (25.9)
T stage (UICC)
†
1 215 (52.2) 59 (27.4) 101 (47.0) 55 (25.6)
2 164 (39.8) 56 (34.1) 73 (44.5) 35 (21.3)
3 22 (5.3) 3 (13.6) 15 (68.2) 4 (18.2)
4 11 (2.7) 3 (27.3) 5 (45.5) 3 (27.3)
Nodal status (UICC)
N- 247 (60.0) 67 (27.1) 117 (47.4) 63 (25.5)
N+ 165 (40.0) 54 (32.7) 77 (46.7) 34 (20.6)
Stage (UICC)
I 165 (40.0) 46 (27.9) 79 (47.9) 40 (24.2)
II 210 (51.0) 68 (32.4) 92 (43.8) 50 (23.8)
III 37 (9.0) 7 (18.9) 23 (62.2) 7 (18.9)
Oestrogen receptor status
Positive 310 (75.2) 88 (28.4) 146 (47.1) 76 (24.5)
Negative 89 (21.6) 28 (31.5) 45 (50.6) 16 (18.0)
Unknown 13 (3.2) 5 (38.5) 3 (23.1) 5 (38.5)
Progesterone receptor status
Positive 247 (60.0) 71 (28.7) 113 (45.7) 63 (25.5)
Negative 150 (36.4) 45 (30.0) 76 (50.7) 29 (19.3)
Unknown 15 (3.6) 5 (33.3) 5 (33.3) 5 (33.3)
Morphological type
Ductal 268 (65.0) 75 (28.0) 132 (49.3) 61 (22.8)
Lobular 70 (17.0) 28 (40.0) 27 (38.6) 15 (21.4)
Other types 74 (18.0) 18 (24.3) 35 (47.3) 21 (28.4)
Adjuvant treatment
Radiotherapy 243 (59.0) 74 (30.5) 110 (45.3) 59 (24.3)
Endocrine therapy 106 (25.7) 28 (26.4) 56 (52.8) 22 (20.8)
Tamoxifen 88 (21.4) 23 (26.1) 45 (51.1) 20 (22.7)
Toremifen 17 (4.1) 5 (29.4) 11 (64.7) 1 (5.9)
Chemotherapy 80 (19.4) 34 (42.5) 31 (38.8) 15 (18.8)
Vital Status
Alive 184 (44.7) 50 (27.2) 88 (47.8) 46 (25.0)
No recurrence 159 (38.6) 41 (25.8) 79 (49.7) 39 (24.5)
Recurrence of breast cancer 25 (6.1) 9 (36.0) 9 (36.0) 7 (28.0)
Death 228 (55.3) 71 (31.1) 106 (46.5) 51 (22.4)
Breast cancer caused death 112 (27.2) 40 (35.7) 49 (43.8) 23 (20.5)
Death with other reasons 116 (28.2) 31 (26.7) 57 (49.1) 28 (24.1)
§Values in the table are number of patients (%).
†UICC = International Union Against Cancer, TNM Classification of Malignant Tumours, Fourth, Fully Revised Edition
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Our study had a median follow-up of nearly 12 years
and it provides data on overall, breast cancer specific
and relapse-free survival. The multivariate analysis of
the combined patient population given either TAM or
chemotherapy showed a statistically significant associa-
tion between the studied rs9282861 SNP and OS,
favouring patients with the homozygous variant AA gen-
otype. However, in a separate analysis of patients receiv-
ing either adjuvant chemotherapy or TAM, the
differences in survival were not statistically significant.
Our finding of improved survival of patients homozy-
gous for the variant SULT1A1 rs9282861 A allele is in
agreement with the hypothesis that the lower catalytic
Figure 1 SULT1A1 rs9282861 genotype and overall survival of
breast cancer patients receiving adjuvant chemotherapy. The
black solid line represents patients homozygous or heterozygous for
the rs9282861 G allele and the black dotted line represents patients
homozygous for the rs9282861 A allele. Adjustments were made for
stage, age, radiation therapy, and hormone receptor status.
Table 2 Associations between the SULT1A1 rs9282861 genotypes, adjuvant treatment and overall survival (OS)
Cases n HR 95% CI P
§ median OS (years)
chemotherapy only 76 13.0
GG or AG 62 1
† 11.0
AA 14 0.33 0.10 to 1.09 0.068 16.0
TAM only 65 9.2
GG or AG 47 1
‡ 8.2
AA 18 0.53 0.27 to 1.08 0.079 11.9
chemotherapy/TAM
¥ 145 10.0
GG or AG 112 1
† 9.1
AA 33 0.50 0.29 to 0.88 0.015 13.7
Abbreviations: TAM = tamoxifen
§P was based on Cox proportional analysis
†Reference value; HRs adjusted for age and stage at diagnosis, radiation therapy, and hormone receptor status
‡Reference value; HRs adjusted for age and stage at diagnosis, and radiation therapy
¥Four patients received chemotherapy and TAM
Figure 2 SULT1A1 rs9282861 genotype and overall survival of
breast cancer patients receiving adjuvant tamoxifen. The black
solid line represents patients homozygous or heterozygous for the
rs9282861 G allele and the black dotted line represents patients
homozygous for the rs9282861 A allele. Adjustments were made for
stage, age, and radiation therapy.
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genotype might lead to slower elimination of 4-OH-
TAM, thus lengthening its duration of action. On the
other hand, based on our results rs9282861 genotype is
not a distinct predictive factor for the efficacy of adju-
vant TAM or chemotherapy since BCSS did not differ
significantly. As we analyzed all the 412 patients, includ-
ing those who were given only adjuvant radiotherapy
and those who did not receive any type of adjuvant
treatment, there was no difference in OS or BCSS.
Therefore, the rs9282861 genotype did not seem to be
an independent prognostic factor in our unselected
breast cancer patient population. Instead, the rs9282861
genotype emerged as a statistically significant prognostic
factor as we analyzed OS specifically for the patients
given medical adjuvant treatment.
However, our finding is not supported by previous clin-
ical studies [8,9,11,26,27]. To explain the improved OS of
the carriers of the wild-type G allele, Nowell et al. [8]
suggested in their study of TAM treated breast cancer
patients (n = 160) that the sulfated form of 4-OH-TAM
is reabsorbed in the kidney and further desulfated in the
breast tumours by steroid sulfatase, thus prolonging the
duration of action of the active 4-OH-TAM. Another
possible explanation was that the high-activity allele
induces global expression of the SULT1A1 enzyme, fol-
lowed by increased elimination of potentially harmful
substrates.
In another study with a similar follow-up time as our
study but with a slightly different approach, Wegman
et al. [11] investigated the influence of the SULT1A1
rs9282861 genotype on RFS of breast cancer patients
treated with adjuvant TAM or no endocrine therapy. In
the group of TAM-treated patients (n = 112) there was
a trend of lower risk of distant recurrence among car-
riers of the wild-type GG genotype. It is noteworthy
that in their study genotyping was made from tumour
tissue, which may cause a risk of genotype misclassifica-
tion. However, the most plausible reason for the discor-
dant results between different studies is the lack of
power due to small sample sizes.
The outcome of TAM therapy is probably not solely
determined by a single SNP but a combination of several
genetic factors. In addition to sulfation by SULTs, glucur-
onidation of TAM and its metabolites by uridine dipho-
sphate glucuronosyltransferases (UGTs) offers a way of
substrate elimination through the bile. Glucuronidation
is probably the most effective way to excrete TAM and
its derivatives [28]. In fact, the UGT2B15 high activity
genotype has been associated with an increased risk of
recurrence and poorer survival in a group of TAM-trea-
ted patients [26]. Furthermore, several other UGTs
(UGT1A4, UGT2B7, UGT1A8 and UGT1A10) have been
reported to be active against 4-OH-TAM [29,30].
Polymorphisms associated with the CYP genes, espe-
cially CYP2D6, may also have a substantial effect on the
outcome of TAM therapy; CYP2D6 contributes to the
formation of 4-OH-TAM in human liver [31]. Moreover,
TAM is metabolized to 4-desmethyl-TAM via CYP-
dependent pathway by CYP3A4 and secondarily to
endoxifen by CYP2D6, and decreased CYP2D6 enzyme
activity has been associated wit hw o r s ee v e n t - f r e es u r v i -
val and disease-free survival in patients treated with adju-
vant TAM [32], although contradictory results have also
been reported [11]. This complexity of TAM metabolism
may explain the conflicting results in different studies.
There appears to be no studies on the role of SULT1A1
polymorphism in the pharmacokinetics of chemothera-
peutic regimens, and the mechanism of this potential
association is unclear. It is known that heterocyclic
amines are activated by SULTs [33]. The sulfonate group
is often transferred to oxygen, which is frequently in the
form of hydroxyl group [33]. In theory, 4-OHCPA might
serve as a substrate to SULT1A1 and possessing the
high-activity SULT1A1 allele would increase the rate of
elimination of CPA, thus decreasing the individual’s
exposure to its cytotoxic effects. However, none of the
chemotherapeutic drugs given in the CMF regimen are
Figure 3 Overall survival of combined patient population
receiving adjuvant tamoxifen or chemotherapy according to
the SULT1A1 rs9282861 genotype. The black solid line represents
patients homozygous or heterozygous for the rs9282861 G allele
and the black dotted line represents patients homozygous for the
rs9282861 A allele. Adjustments were made for stage, age, radiation
therapy, and hormone receptor status.
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date there are no pharmacokinetic or in vitro data avail-
able to support this hypothesis.
Our results clearly indicate that there may be an asso-
ciation between the SULT1A1 rs9292861 genotype and
the survival of breast cancer patients, but further studies
are warranted due to a relatively small sample size. Lack
of specific data on the other medications used by the
patients is also a limitation of our study. For example,
concomitant use of CYP2D6 inhibitors, including selec-
tive serotonin reuptake inhibitor (SSRI) antidepressants,
may reduce the efficacy of TAM [34]. However, the
influence of this potential confounding factor is antici-
pated to be minor since the use of SSRIs was uncom-
mon in the 1990s.
Lastly, local radiotherapy was given to 77 patients
(95.1%) receiving chemotherapy and to 47 patients (72.3%)
treated with TAM. In the univariate analysis, the
rs9282861 genotype was not associated with any differ-
ences in survival among patients who were given adjuvant
radiotherapy but no adjuvant chemotherapy or hormonal
therapy (n = 230). It is unlikely that radiotherapy interacts
with SULT1A1 enzyme, which would result in various sur-
vival outcomes between SULT1A1 genotypes.
Conclusions
In summary, breast cancer patients with the SULT1A1
rs9282861 homozygous variant AA genotype and treated
with either adjuvant TAM or chemotherapy had statisti-
cally significantly better OS compared with the carriers
of other rs9282861 genotypes. However, the association
was not statistically significant in the multivariate analy-
sis conducted among patients given only chemotherapy
or TAM. Moreover, the BCSS did not differ significantly
between the carriers of different rs9282861 genotypes.
Further prospective studies with larger samples are
therefore needed to assess the real relevance of the pre-
sent findings and their potential influence on treatment
outcomes of breast cancer patients.
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